Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vaccines For Uninsured Adults Initiative Proposed In Biden’s Federal Budget For 2023

Executive Summary

Biden budget proposal also addresses consolidating all Medicare coverage for vaccines under Part B, providing Medicare and Medicaid 'explicit' authority to cover vaccines approved under emergency use authorizations without cost sharing, and increasing 340B spending on program oversight.

You may also be interested in...

Plea To FDA From Those Injured By COVID-19 Vaccines: 'Please Hear Us'

Individuals who developed symptoms similar to long COVID after vaccination say their injuries are being ignored. Speaking at the agency’s VRBPAC meeting, they note the need for research and compensation for these injuries. To date, no COVID-19 vaccine injury claims have been reimbursed under federal compensation programs.

US Rx Spending Growth Projected To Stay Modest; Will Political Debate Change?

The latest update by the US Centers for Medicare & Medicaid Services to national health care spending forecasts continues to put prescription drugs in line with – or even slightly below – overall growth rates. Of course, that likely won’t change the political attention to the issue in 2022.

340B Court Ruling Offers Manufacturers Short-Term Reprieve In Contract Pharmacy Dispute

Federal court vacates enforcement letter to Lilly from HRSA, but the decision was not completely favorable to pharma. It also offers the view that the law does not allow manufacturers to restrict 340B discounts to hospitals using multiple contract pharmacies.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts